Effects of fish oil supplements in NIDDM subjects. Controlled study - PubMed (original) (raw)

Clinical Trial

Effects of fish oil supplements in NIDDM subjects. Controlled study

T J Hendra et al. Diabetes Care. 1990 Aug.

Abstract

The aim of this study was to evaluate the effects of a fish oil preparation (MaxEPA) on hemostatic function and fasting lipid and glucose levels in non-insulin-dependent diabetic (NIDDM) subjects. Eighty NIDDM outpatients aged 55.9 yr (mean SD 11.5 yr) participated in a prospective double-blind placebo-controlled study of MaxEPA capsules (10 g/day) or olive oil (control) treatment over 6 wk. Patients received either MaxEPA or olive oil in addition to preexisting therapy. Metabolic and hemostatic variables were measured before treatment and after 3 and 6 wk. Platelet membrane eicosapentaenoic acid (EPA) content increased in the treatment group (P less than 0.001). MaxEPA supplementation was associated with a significant fall in total triglycerides (P less than 0.001) but did not affect total cholesterol (P = 0.7) compared with control treatment. Fasting plasma glucose increased after 3 wk (P = 0.01) but not after 6 wk (P = 0.17) treatment with MaxEPA. Spontaneous platelet aggregation in whole blood fell in the MaxEPA group (P less than 0.02) after 6 wk, but there were no changes in agonist-induced platelet aggregation, thromboxane generation in platelet-rich plasma, or plasma beta-thromboglobulin and platelet factor IV levels. An increase in clotting factor VII (P = 0.02), without changes in fibrinogen or factor X levels, occurred in the MaxEPA group. Similar reductions in blood pressure were observed in both groups. Dietary supplementation with MaxEPA capsules (10 g/day) in NIDDM subjects is associated with improvement in hypertriglyceridemia but with deleterious effects in factor VII and blood glucose levels. Most indices of platelet function are unaffected by this therapy.

PubMed Disclaimer

Cited by

Omega-3 fatty acids. Current status in cardiovascular medicine.
Schmidt EB, Dyerberg J. Schmidt EB, et al. Drugs. 1994 Mar;47(3):405-24. doi: 10.2165/00003495-199447030-00003. Drugs. 1994. PMID: 7514972 Review.
Omega-3 Fatty Acids Effects on Inflammatory Biomarkers and Lipid Profiles among Diabetic and Cardiovascular Disease Patients: A Systematic Review and Meta-Analysis.
Natto ZS, Yaghmoor W, Alshaeri HK, Van Dyke TE. Natto ZS, et al. Sci Rep. 2019 Dec 11;9(1):18867. doi: 10.1038/s41598-019-54535-x. Sci Rep. 2019. PMID: 31827125 Free PMC article.
Long-chain omega-3 fatty acids, fish intake, and the risk of type 2 diabetes mellitus.
Kaushik M, Mozaffarian D, Spiegelman D, Manson JE, Willett WC, Hu FB. Kaushik M, et al. Am J Clin Nutr. 2009 Sep;90(3):613-20. doi: 10.3945/ajcn.2008.27424. Epub 2009 Jul 22. Am J Clin Nutr. 2009. PMID: 19625683 Free PMC article.
Effects of n-3 Polyunsaturated Fatty Acid Supplementation on Cardiovascular Indices in Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials.
Li R, Wang Y, Xu J, Yu J, Li B. Li R, et al. Rev Cardiovasc Med. 2025 Feb 18;26(2):25882. doi: 10.31083/RCM25882. eCollection 2025 Feb. Rev Cardiovasc Med. 2025. PMID: 40026502 Free PMC article.
n-3 fatty acids and lipoproteins: comparison of results from human and animal studies.
Harris WS. Harris WS. Lipids. 1996 Mar;31(3):243-52. doi: 10.1007/BF02529870. Lipids. 1996. PMID: 8900453 Review.

Effects of fish oil supplements in NIDDM subjects. Controlled study - PubMed (original) (raw)